Truist Securities maintains ArriVent BioPharma at Buy, raises price target to $24 from $21

Truist Securities maintained its Buy rating on ArriVent BioPharma and increased its price target to $24 from $21, representing a 14.3% increase. This new target suggests a 69.5% upside from the stock's Nov 9 close of $14.16. Other recent analyst price targets for the company range from $29 to $30.

Original reporting
Published Nov 10, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Truist Securities maintains ArriVent BioPharma at Buy, raises price target to $24 from $21 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The price‑target increase suggests a potential upside of roughly 70% from current levels, but without a catalyst the effect may be muted.

02

Market read

Analyst target adjustments are modest drivers of price movement for small caps; traders may watch for any follow‑up catalyst.

03

What to watch

No recent clinical data released; the raise is purely analyst opinion.

Relevance 6/10Novelty 5/10Timing: post-market today

Background

ArriVent BioPharma is a micro‑cap biotech listed on NASDAQ. Analyst coverage is limited, making target changes notable for traders.

Market effects

May slightly lift sentiment in the small‑cap biotech sector.

Limited to U.S. biotech investors.

Minimal

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • Truist Securities

    Equity research firm that issued the target raise.

  • ArriVent BioPharma

    Biopharmaceutical company focused on oncology therapies.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.